BMJ 2006;333:869-870 (28 October), doi:10.1136/bmj.39009.366736.80
Editorial
Age related macular degeneration
Better tools are needed to measure quality of life and visual outcomes
| The first 150 words of the full text of this article appear below. |
Wet (also known as neovascular or exudative) age related macular degeneration is a common condition of poorly understood aetiology that affects around two million elderly people in Europe.1 In the United Kingdom, in about a quarter of a million people wet macular degeneration causes bilateral visual impairment of sufficient severity that they are registered as partially sighted or blind.2 If only one eye is affected the onset of disease may go unnoticed by the patient. Wet macular degeneration is usually bilateral though, and when the second eye becomes affected the impact on the patient is devastating.3
Good vision is often taken for granted. It is an important prerequisite for a socially fulfilling and active lifestyle. Wet macular degeneration affecting both eyes has serious consequences for quality of life. The psychosocial and functional impact of sight loss due to this condition is reviewed in a paper by Mitchell and Bradley
Usha Chakravarthy, professor of ophthalmology and vision sciences
Centre for Vision Science, Queen's University of Belfast, Belfast BT12 6BA
(u.chakravarthy@qub.ac.uk)
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
StumbleUpon 
Technorati What's this?
Relevant Article
- Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis
- Elaine W-T Chong, Tien Y Wong, Andreas J Kreis, Julie A Simpson, and Robyn H Guymer
BMJ 2007 335: 755.[Abstract] [Full Text] [PDF]
This article has been cited by other articles:
-
Chong, E. W-T, Wong, T. Y, Kreis, A. J, Simpson, J. A, Guymer, R. H
(2007). Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. BMJ
335: 755-755
[Abstract] [Full text]
Rapid Responses:
Read all Rapid Responses
- Age-related macular degeneration: better tools are available to measure quality of life and visual outcomes
- Clare Bradley, et al.
bmj.com, 27 Oct 2006 [Full text] - Monoclonal antibodies to vascular endothelial growth factor (VEGF) provide vision for the future
- Amit Patel
bmj.com, 30 Oct 2006 [Full text] - The role of generic measures of health status in ARMD
- John E Brazier, et al.
bmj.com, 14 Nov 2006 [Full text] - Health status tools do not measure the impact of macular degeneration (AMD) on QoL: A reply to Professor Brazier and colleagues.
- Jan Mitchell, et al.
bmj.com, 23 Nov 2006 [Full text]
This Article
- Full text
- Respond to this article
- Read responses to this article
- Alert me when this article is cited
- Alert me when responses are posted
- Alert me when a correction is posted
- View citation map
Services
- Email this article to a friend
- Find similar articles in BMJ
- Find similar articles in ISI Web of Science
- Find similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
- Read articles citing this article
- Citing Articles via Web of Science (1)
- Citing Articles via Google Scholar
Google Scholar
PubMed
Related Content
-
Ophthalmology
-
Sociology
-
Disability
- Epidemiologic studies
- Relevant Article
- Find this article in its weekly table of contents
Bookmark with
What's new
Latest blogs
Find BMJ on:
Services
Tools
Online poll
Resources
Rapid responses for this article
- Age-related macular degeneration: better tools are available to measure quality of life and visual outcomes Clare Bradley, et al.
- Monoclonal antibodies to vascular endothelial growth factor (VEGF) provide vision for the future Amit Patel
- The role of generic measures of health status in ARMD John E Brazier, et al.
Print issues
